Docosahexenoic Acid (DHA) Supplementation and Cardiovascular Disease in Men With High Triglycerides

Completed · Not applicable

Conditions studied: Hypertriglyceridemia

In brief

The purpose of this study is to determine the effects of supplementing diets of hyperlipidemic men with DHA (docosahexenoic acid) on risk factors for cardiovascular disease. We hypothesize that supplementing diets of hyperlipidemic men with DHA will decrease the plasma concentrations of CRP (C-reactive protein), inflammatory cytokines, and soluble adhesion molecules. We further hypothesize that DHA supplementation will decrease serum triglyceride concentrations and increase HDL concentration.

Key facts

Study ID

NCT00728338

Run by

USDA, Western Human Nutrition Research Center

People needed

40

Starts

2003-06-01

Expected to finish

2005-11-01

Last updated by the study team

2008-08-08

Who can join

Age: 39 and older, up to 66. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• fasting serum triglyceride values of 150-400 mg/dL
• total cholesterol < 300 mg/dL
• LDL-cholesterol < 220 mg/dL
• BMI between 22 and 35 Kg/m2

You may not qualify if…

• anti-inflammatory medications including steroids
• antihypertensives
• non sulfonyl urea medications for diabetes mellitus
• drugs that alter serum triacylglycerols and HDL-C levels (i.e. fibrates)
• niacin supplements
• consumers of illegal substances
• consumers of more than 5 drinks of alcohol per week
• more than one fish meal per week
• dietary supplements of fish oil, flaxseed oil or vitamin C or E

Where it is running

• Usda, Ars, Whnrc — Davis, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.